Scenic Biotech BV announced that Dr. C. A. Oscar Izeboud was appointed as CEO, and former acting CEO and scientific co-founder Dr. Sebastian Nijman took on the role of chief scientific officer.
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, tapped Erik Spek, Ph.D., J.D., as VP, Legal and Intellectual Property.
Akcea Therapeutics Inc., a majority-owned affiliate of Ionis Pharmaceuticals Inc., made William Andrews, M.D., FACP, chief medical officer, effective immediately. Tracy Palmer Berns has joined the company as chief compliance officer, and Dr. Kia Motesharei is now senior VP, business development and corporate strategy.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions, appointed Carrie Ann Cook to the position of senior VP/global head of business development.
Arena Pharmaceuticals Inc. made changes to the company’s research and development leadership team. Dr. Preston Klassen left the company to pursue an opportunity as CEO of a San Diego-based private company. Dr. Chris Cabell, Arena’s senior VP and chief medical officer, assumed the role of executive VP, head of research and development, and chief medical officer.
Inovio appointed two experienced senior executives to lead the company’s growth in the Asia market and to advance the clinical development of its DNA vaccine INO-4800 to combat the COVID-19 pandemic.
Antengene Corp. chose Zhinuan Yu, Ph.D., as corporate VP of biometrics and regulatory enabling functions. Dr. Yu is responsible for providing statistical leadership and strategic regulatory input on company pipeline projects and reports directly to Dr. Jay Mei, chairman and CEO of Antengene.
The board of directors of Oncopeptides AB appointed Marty J. Duvall as CEO. Duvall replaced Jakob Lindberg, who was CEO since the restart of the company in 2011.
STORM Therapeutics, a biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, appointed Dr. Josefin-Beate Holz as clinical advisor and chief medical officer.
Laurent Fischer, M.D., joined Adverum Biotechnologies Inc. as CEO and a member of the board of directors. Leone Patterson, who served for four years in executive leadership roles at Adverum – most recently as CEO – continues to serve as the company’s president.